Intellia Therapeutics, Inc. - Common Stock (NTLA)
$10.71
0.00 (0.00%)
NTLA Stock Quote Delayed 30 Minutes
The Top 5 Stocks Cathie Wood Is Buying This Week
Cathie Wood announced that she would step down as portfolio manager for PRNT and IZRL. That hasn't stopped her from making her usual buys.
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
943.99M
PE Ratio
-1.97
EPS
-5.44
Volume (Avg. Vol.)
6,486
Day's Range
-
52-Week Range
$8.96 - $34.87
Dividend & Yield
N/A (N/A)
NTLA Stock Predictions, Articles, and Intellia Therapeutics, Inc. - Common Stock News
Forget About the Genomic Revolution, the Proteomic Revolution Is Coming
Thanks to one small protein sequencing startup, we're entering a new era of proteomics via NGPS technologies that will enable massively parallel protein sequencing.
Forget About the Genomic Revolution, the Proteomic Revolution Is Coming
Thanks to one small protein sequencing startup, we're entering a new era of proteomics via NGPS technologies that will enable massively parallel protein sequencing.
Gene Editing Stocks: The Trial News Lifting NTLA, CRSP and EDIT Stocks Today
Today, gene editing stocks are getting a big boost after an intriguing data release by Editas for the company's new SLEEK technology.
Gene Editing Stocks: Why EDIT, NTLA, CRSP Stocks Are Climbing Today
Today, investors in gene editing stocks are seeing a lot of green as earnings were announced along with business updates from key players.
Investing in CRISPR Stocks: Ultimate Genetic Editing Guide
The biotech space is on the verge of hypergrowth, thanks to a scientific breakthrough in genetic editing. This is your ultimate guide to understanding and profiting from CRISPR stocks.
This Healthcare Breakthrough Gives Me Chills
In just the last few days, we got word of a healthcare game-changer that will save lives, eradicate much suffering and make investors money.
The Top 7 Gene-Editing Stocks to Buy for the Biggest Scientific Breakthrough of the Century
Doudna's breakthrough in CRISPR has since ushered in a new era of genetic engineering, making these the best gene-editing stocks to buy.
Gene Editing Stocks: Why EDIT, CRSP, NTLA Stocks Continue to Soar
Today, gene editing stocks are soaring amid increasingly bullish sentiment in this sector following strong results from Intellia.
Midday Market Update: 10 Biggest Stock Gainers Today
Good afternoon, investors! We're taking a look at how the market is doing halfway through the day with a midday market update.
Intellia Makes a Splash, Bringing Other CRISPR Stocks Along for the Ride
As a result of this news, NTLA stock is way up, and other genome editing stocks are seeing gains as well.
What Will the Stock Market Do Today? 3 Big Stories to Watch.
So what will the stock market do today? All eyes are on gene-editing stocks like NTLA and on recovering crypto prices.
Gene Editing Stocks: The Big News Lifting EDIT, BNGO, CRSP and NTLA Stocks
Gene editing stocks are getting a boost on Monday morning after Intellia Therapeutics said it was successful using CRISPR gene-editing therapy directed inside the body to an internal organ.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Good morning! Let's get ready for trading to start off strong this week with a look at the biggest pre-market stock movers for Monday!
What Did the Stock Market Do Today? 3 Big Stories to Catch Up On.
So what did the stock market do today? Dogecoin prices and other cryptocurrencies stole the show, and CRISPR stocks sold off.
CRISPR Stocks: The Big Analyst Call Destroying CRSP, NTLA, EDIT Stocks Today
A "sell" rating is one thing, but a price target barely half of the Thursday close? It's no wonder Editas stock is crashing, and taking other gene-editing stocks with it.
Gene Editing Stocks: What BLUE, NTLA, BEAM, CRSP and EDIT Are Doing Today
Gene editing stocks are on the move Wednesday with investors taking extra interest in biotech companies on news from two major players.
A Highly Specialized Gene Editing Stock with a Clear Pathway to Big Gains
It’s been a long, long journey… but we are finally at the point where genomics is ready to change the world.
